This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Draisma G et al. (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868–878
Schroder FH and Roobol M (2006) Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. Eur Urol 49: 412–413
Steyerberg EW et al.: Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol, in press
Schroder FH et al. (2006) Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49: 460–465
Acknowledgements
The synopsis was written by Sandra Ford, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Chris Bangma is an incidental advisor to Beckman-Coulter Europe.
Rights and permissions
About this article
Cite this article
Bangma, C. PSA level changes over time in men with an initial PSA level of ≤4 ng/ml. Nat Rev Urol 3, 520–521 (2006). https://doi.org/10.1038/ncpuro0563
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0563